BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19652059)

  • 1. Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
    Tefferi A; Verstovsek S; Barosi G; Passamonti F; Roboz GJ; Gisslinger H; Paquette RL; Cervantes F; Rivera CE; Deeg HJ; Thiele J; Kvasnicka HM; Vardiman JW; Zhang Y; Bekele BN; Mesa RA; Gale RP; Kantarjian HM
    J Clin Oncol; 2009 Sep; 27(27):4563-9. PubMed ID: 19652059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.
    Daver N; Shastri A; Kadia T; Newberry K; Pemmaraju N; Jabbour E; Zhou L; Pierce S; Cortes J; Kantarjian H; Verstovsek S
    Leuk Res; 2014 Sep; 38(9):1126-9. PubMed ID: 25047979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase-2 trial of low-dose pomalidomide in myelofibrosis.
    Begna KH; Mesa RA; Pardanani A; Hogan WJ; Litzow MR; McClure RF; Tefferi A
    Leukemia; 2011 Feb; 25(2):301-4. PubMed ID: 21052089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Transfusion independence achieved with pomalidomide therapy in a patient with primary myelofibrosis].
    Edahiro Y; Gotoh A; Inano T; Tsutsui M; Tsukune Y; Yasuda H; Komatsu N
    Rinsho Ketsueki; 2018; 59(3):323-325. PubMed ID: 29618692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia.
    Tefferi A; Hudgens S; Mesa R; Gale RP; Verstovsek S; Passamonti F; Cervantes F; Rivera C; Tencer T; Khan ZM
    Clin Ther; 2014 Apr; 36(4):560-6. PubMed ID: 24636526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.
    Daver N; Shastri A; Kadia T; Quintas-Cardama A; Jabbour E; Konopleva M; O'Brien S; Pierce S; Zhou L; Cortes J; Kantarjian H; Verstovsek S
    Leuk Res; 2013 Nov; 37(11):1440-4. PubMed ID: 23890523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis.
    Pardanani A; Begna K; Finke C; Lasho T; Tefferi A
    Am J Hematol; 2011 Apr; 86(4):343-5. PubMed ID: 21442636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
    Quintás-Cardama A; Kantarjian HM; Manshouri T; Thomas D; Cortes J; Ravandi F; Garcia-Manero G; Ferrajoli A; Bueso-Ramos C; Verstovsek S
    J Clin Oncol; 2009 Oct; 27(28):4760-6. PubMed ID: 19720904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response.
    Luo X; Xu Z; Li B; Qin T; Zhang P; Zhang H; Fang L; Pan L; Hu N; Qu S; Zhang Y; Huang G; Peter Gale R; Xiao Z
    Blood Cancer J; 2018 Jan; 8(1):9. PubMed ID: 29335406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.
    Tefferi A; Al-Ali HK; Barosi G; Devos T; Gisslinger H; Jiang Q; Kiladjian JJ; Mesa R; Passamonti F; McMullin MF; Ribrag V; Schiller G; Vannucchi AM; Zhou D; Reiser D; Zhong J; Gale RP
    Leukemia; 2017 Apr; 31(4):896-902. PubMed ID: 27773929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.
    Larocca A; Montefusco V; Bringhen S; Rossi D; Crippa C; Mina R; Galli M; Marcatti M; La Verde G; Giuliani N; Magarotto V; Guglielmelli T; Rota-Scalabrini D; Omedé P; Santagostino A; Baldi I; Carella AM; Boccadoro M; Corradini P; Palumbo A
    Blood; 2013 Oct; 122(16):2799-806. PubMed ID: 23954889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase1/-2 study of Pomalidomide in myelofibrosis.
    Mesa RA; Pardanani AD; Hussein K; Wu W; Schwager S; Litzow MR; Hogan WJ; Tefferi A
    Am J Hematol; 2010 Feb; 85(2):129-30. PubMed ID: 20052748
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis.
    Chihara D; Masarova L; Newberry KJ; Maeng H; Ravandi F; Garcia-Manero G; Ferrajoli A; Cortes J; Kantarjian H; Verstovsek S
    Leuk Res; 2016 Sep; 48():1-5. PubMed ID: 27416326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome of pomalidomide therapy in myelofibrosis.
    Begna KH; Pardanani A; Mesa R; Litzow MR; Hogan WJ; Hanson CA; Tefferi A
    Am J Hematol; 2012 Jan; 87(1):66-8. PubMed ID: 22081489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia.
    Mesa RA; Elliott MA; Schroeder G; Tefferi A
    Mayo Clin Proc; 2004 Jul; 79(7):883-9. PubMed ID: 15244384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of low-dose thalidomide and prednisone combined with or without danazol for the treatment of primary myelofibrosis-associated anemia].
    Xu J; Xu Z; Qin T; Li B; Fang L; Zhang H; Hu N; Pan L; Qu S; Zhang Y; Xiao Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Aug; 35(8):698-702. PubMed ID: 25152115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Responses to pomalidomide and placebo in myelofibrosis-related anaemia.
    Ross DM
    Leukemia; 2017 Mar; 31(3):532-533. PubMed ID: 27932792
    [No Abstract]   [Full Text] [Related]  

  • 18. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.
    Mesa RA; Steensma DP; Pardanani A; Li CY; Elliott M; Kaufmann SH; Wiseman G; Gray LA; Schroeder G; Reeder T; Zeldis JB; Tefferi A
    Blood; 2003 Apr; 101(7):2534-41. PubMed ID: 12517815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone.
    Duan M; Zhou D
    Hematology; 2019 Dec; 24(1):516-520. PubMed ID: 31242816
    [No Abstract]   [Full Text] [Related]  

  • 20. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Ahmadi T; Ukropec J; Kampfenkel T; Schecter JM; Qiu Y; Amin H; Vermeulen J; Carson R; Sonneveld P;
    Lancet Oncol; 2021 Jun; 22(6):801-812. PubMed ID: 34087126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.